Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • Equities
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Macro Notification
  • Management
  • Market Summary
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Mining
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week

Michael Horton

2106 posts
Group By Ticker
Sort By
Newest | Oldest
Read More
1 minute read
  • Trading Ideas

Top 15 Trending Stocks On WallStreetBets As Of Friday, September 9, 2022 (Via Swaggy Stocks)

By Michael Horton
September 9, 4:24 PM
Data from https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment   Bed Bath & Beyond (BBBY) Tesla (TSLA) Apple (AAPL) GameStop (GME) Invesco QQQ Trust (QQQ) DocuSign (DOCU) Digital

AAPL

Read More
1 minute read
  • News

Spectrum Pharmaceuticals Receives FDA Approval for ROLVEDON™ (eflapegrastim-xnst) Injection

By Michael Horton
September 9, 4:19 PM
First novel Long-Acting GCSF (LA-GCSF) product approved in over 20 years ROLVEDON™ developed using proprietary LAPSCOVERY™ technology with a differentiated molecular structure and proven safety and

SPPI

Read More
1 minute read
  • News

Spectrum Pharmaceuticals’ Website Says ROLVEDON Has Been Approved

By Michael Horton
September 9, 4:16 PM
https://www.sppirx.com/

SPPI

Read More
1 minute read
  • News
  • Offerings

Viridian Therapeutics Files For Mixed-Securities Shelf Offering, Size Not Disclosed

By Michael Horton
September 9, 4:08 PM
-SEC Filing

VRDN

Read More
2 minute read
  • News

Minerva Neurosciences Announces Listing Transfer to Nasdaq Capital Market

By Michael Horton
September 9, 4:06 PM
Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported a listing transfer from

NERV

Read More
1 minute read
  • News
  • Offerings

Xos Files For Resale Of Up To 33.2M Shares By Selling Securityholder

By Michael Horton
September 8, 5:41 PM
-Reuters

XOS

Read More
1 minute read
  • News
  • Offerings

Dolphin Entertainment Files Prospectus Related To Issuance By Co. Of An Aggregate Of Up To 3.1M Shares of Common Stock

By Michael Horton
September 8, 5:37 PM
-Reuters

DLPN

Read More
1 minute read
  • Legal
  • News

Amplify Energy Reaches Agreement with State of California to Resolve Matters Associated with Southern California Pipeline Incident, To Pay $4.9M Fine To Be Distributed Among State Of California

By Michael Horton
September 8, 5:24 PM
Amplify Energy Corp. ("Amplify" or the "Company") (NYSE:AMPY) today announced that it has reached an agreement with the State of California to resolve all criminal matters involving the Company and

AMPY

Read More
1 minute read
  • News

Oramed Pharmaceuticals Says On Sept. 1, 2022 Co. And Its Subsidiary Entered Into Non-Binding Memorandum Of Agreement With Medicox, Set Out Basic Commercial Understandings Between Parties That Would Form Basis Of Definitive Distribution License Agreemen…

By Michael Horton
September 8, 5:13 PM
-Reuters

ORMP

Read More
1 minute read
  • Guidance
  • News

DHI Group Raises FY Revenue Guidance At 2022 Analyst Day; Sees Q3 Revenue Up 20%-23% At $37M-$38M, Says Now Expect FY Total Revenue To Be In Range Of $148M-$149M-

By Michael Horton
September 8, 5:07 PM
-Reuters

DHX

Posts pagination

Previous 1 … 159 160 161 … 211 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service